This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-14 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Investigative applications == In bioarchaeological research and in forensic investigations, osteons in a bone fragment can be used to determine the sex of an individual and age, as well as aspects of taxonomy, diet, health and motor history. Osteons and their arrangement vary according to taxon, so that genus and sometimes species can be differentiated using a bone fragment not otherwise identifiable. However, there is considerable variability among the different bones of a skeleton, and features of some faunal osteons overlap with those of human osteons; therefore, examination of osteons is not of primary use in the analyses of osteological remains. More research is needed, but osteohistology has the potential to positively affect the studies in bioarchaeology, paleontology and forensic investigations. In recent decades, osteohistological studies of dinosaur fossils have been used to address a number of issues, such as the periodicity of growth of dinosaurs and whether it was uniform across species and the question of whether dinosaurs were warm-blooded or not.
=== Qigong === Qigong and Chinese medicine place huge emphasis on a form of energy called 精 (pinyin: jīng, also a morpheme denoting "essence" or "spirit") – which one attempts to develop and accumulate. "Jing" is sexual energy and is considered to dissipate with ejaculation, so masturbation is considered "energy suicide" amongst those who practice this art. According to Qigong theory, energy from many pathways/meridians becomes diverted and transfers itself to the sexual organs during sexual excitement. The ensuing orgasm and ejaculation will then finally expel the energy from the system completely. The Chinese proverb 一滴精，十滴血 (pinyin: yì dī jīng, shí dī xuè, literally: a drop of semen is equal to ten drops of blood) illustrates this point. The scientific term for semen in Chinese is 精液 (pinyin: jīng yè, literally: fluid of essence/jing) and the term for sperm is 精子 (pinyin: jīng zǐ, literally: basic element of essence/jing), two modern terms with classical referents.
The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction. Treatment must be instituted rapidly on clinical suspicion of the onset of malignant hyperthermia.
The idea of a guerrilla organization was conceived as early as October 1941, months before the Philippines' entry to World War II. As early as 1941, Juan Feleo, a well-known peasant leader and member of the Partido Komunista ng Pilipinas (PKP), had begun to mobilize peasants in his home province of Nueva Ecija for the conflict. Pedro Abad Santos, The founding member of the Socialist Party of the Philippines, had also ordered Luis Taruc to mobilize forces in Pampanga. At the outbreak of World War II in the Philippines and the capture of Manila, top-ranking leaders of the PKP were captured by the Japanese military. Crisanto Evangelista, its founder, was among those who were captured and executed in 1942. Abad Santos was similarly captured but was released in 1943. Dr. Vicente Lava took the reins of the PKP and tried to re-organize the party. In February 1942, a "struggle conference" was held in Cabiao, Nueva Ecija to discuss organization, strategy, and tactics. Members of the PKP, the Popular Front Party, the League for the Defense of Democracy, KPMP, AMT, and KAP convened to create a structure for unified resistance against the Japanese. A united front tactic was agreed upon as a means of attracting the broadest sections of population, not necessarily communists. A three-front resistance was agreed upon: military, political, and economic. The military aim was to harass the Japanese continuously and keep it off-balance so as to prevent it from focusing on activities aimed at winning the goodwill of the people.
Sources: en.wikipedia.org
== Chemerin-derived peptides == A particular synthetic chemerin-derived peptide, termed C15, was developed at Oxford University. It showed anti-inflammatory activities. Intraperitoneal administration of C15 (0.32 ng/kg) to mice before zymosan challenge conferred significant protection against zymosan-induced peritonitis, suppressing neutrophil (63%) and monocyte (62%) recruitment with a concomitant reduction in proinflammatory mediator expression. C15 was found to promote phagocytosis and efferocytosis in peritoneal macrophages at picomolar concentrations. C15 enhanced macrophage clearance of microbial particles and apoptotic cells by factor of 360% in vitro. Another chemerin-derived peptide, termed C-20, was developed at the Shenzhen Institute of Advanced Technology. Administration C-20 uncovered its high affinity binding to chemerin receptors CMKLR1 and GPR1, mimicking chemerin’s activity but with lower potency. C-20 triggered receptor internalization, promoted chemotaxis, and mildly suppressed hormone production (testosterone and progesterone), suggesting its potential as a tool to study chemerin-related signaling pathways.
Impetigo herpetiformis Intrahepatic cholestasis of pregnancy (cholestasis of pregnancy, jaundice of pregnancy, obstetric cholestasis, prurigo gravidarum) Linea nigra Pemphigoid gestationis (gestational pemphigoid, herpes gestationis) Prurigo gestationis (Besnier prurigo, early-onset prurigo of pregnancy, linear IgM dermatosis of pregnancy, papular dermatitis of pregnancy, prurigo of pregnancy, Spangler's papular dermatitis of pregnancy) Pruritic folliculitis of pregnancy Pruritic urticarial papules and plaques of pregnancy (late-onset prurigo of pregnancy, polymorphic eruption of pregnancy, PUPPP syndrome, toxemic rash of pregnancy, toxic erythema of pregnancy) Striae gravidarum
=== Effects === In general, MDMA users report feeling the onset of subjective effects within 30 to 60 minutes of oral consumption and reaching peak effect at 75 to 120 minutes, which then plateaus for about 3.5 hours. The desired short-term psychoactive effects of MDMA have been reported to include:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.